URGN
UroGen Pharma Ltd
NASDAQ: URGN · HEALTHCARE · BIOTECHNOLOGY
$23.83
+2.10% today
Updated 2026-04-30
Market cap
$1.14B
P/E ratio
—
P/S ratio
10.35x
EPS (TTM)
$-3.19
Dividend yield
—
52W range
$3 – $30
Volume
0.8M
UroGen Pharma Ltd (URGN) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-2.56M | $-4.12M | $-7.17M | $4.19M | $-9.57M | $-37.33M | $-71.02M | $-105.89M | $-84.89M | $-87.56M | $-76.38M | $-96.77M | $-162.44M |
| Capital expenditures | $57000.00 | $24000.00 | $301000.00 | $695000.00 | $271000.00 | $560000.00 | $325000.00 | $1.22M | $752000.00 | $254000.00 | $194000.00 | $295000.00 | $289000.00 |
| Depreciation | $18000.00 | $30000.00 | $113000.00 | $213000.00 | $207000.00 | $417000.00 | $1.32M | $2.04M | $1.77M | $1.82M | $1.71M | $1.19M | — |
| Stock-based comp | $541000.00 | $293000.00 | $449000.00 | $1.97M | $6.30M | $30.64M | $29.97M | $28.02M | $23.11M | $10.58M | $9.34M | $13.11M | $11.96M |
| Free cash flow | $-2.61M | $-4.14M | $-7.48M | $3.49M | $-9.84M | $-37.89M | $-71.34M | $-107.10M | $-85.64M | $-87.81M | $-76.57M | $-97.06M | $-162.73M |
| Investing cash flow | $-89000.00 | $-1000.00 | $-301000.00 | $-793000.00 | $-36.38M | $35.29M | $-145.59M | $93.24M | $4.07M | $1.06M | $-953000.00 | $-20.61M | — |
| Financing cash flow | $3.47M | $4.95M | $21.58M | $-9000.00 | $61.59M | $66.42M | $165.25M | $16.53M | $72.32M | $97.13M | $116.93M | $194.62M | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | $64.37M | $-51.36M | $3.88M | $-8.50M | $10.63M | — | — | — |